English Journal

B-Raf and CRHR1 Internalization Mediate Biphasic ERK1/2 Activation by CRH in Hippocampal HT22 Cells.

Bonfiglio JJ, Inda C, Senin S, Maccarrone G, Refojo D, Giacomini D, Turck CW, Holsboer F, Arzt E, Silberstein S.SourceInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA), CONICET, Partner Institute of the Max Planck Society, Godoy Cruz 2390, C1425FQA Buenos Aires, Argentina. ssilberstein@fbmc.fcen.uba.ar.
Molecular endocrinology (Baltimore, Md.).Mol Endocrinol.2013 Mar;27(3):491-510. doi: 10.1210/me.2012-1359. Epub 2013 Jan 31.
CRH is a key regulator of neuroendocrine, autonomic, and behavioral response to stress. CRH-stimulated CRH receptor 1 (CRHR1) activates ERK1/2 depending on intracellular context. In a previous work, we demonstrated that CRH activates ERK1/2 in limbic areas of the mouse brain (hippocampus and basolat
PMID 23371389

Cyclin-dependent kinase 5 promotes the stability of corneal epithelial cell junctions.

Arpitha P, Gao CY, Tripathi BK, Saravanamuthu S, Zelenka P.SourceNational Eye Institute, NIH, Building 5635, Room 1S-02, Fishers Lane, Rockville, MD.
Molecular vision.Mol Vis.2013;19:319-32. Epub 2013 Feb 7.
PURPOSE: Although cyclin-dependent kinase 5 (Cdk5) inhibits the formation of junctions containing N-cadherin, the effect of Cdk5 on junctions containing E-cadherin is less clear. The present study investigates the functional significance of Cdk5 in forming and maintaining cell-cell stability in corn
PMID 23401660

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

Morales-Corraliza J, Schmidt SD, Mazzella MJ, Berger JD, Wilson DA, Wesson DW, Jucker M, Levy E, Nixon RA, Mathews PM.SourceCenter for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA. jmorales-corraliza@nki.rfmh.org
Neurobiology of aging.Neurobiol Aging.2013 Jan;34(1):137-45. doi: 10.1016/j.neurobiolaging.2012.04.007. Epub 2012 May 18.
Although anti-human β-amyloid (Aβ) immunotherapy clears brain β-amyloid plaques in Alzheimer's disease (AD), targeting additional brain plaque constituents to promote clearance has not been attempted. Endogenous murine Aβ is a minor Aβ plaque component in amyloid precursor protein (APP) transge
PMID 22608241